Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

USP Responding To Congress’ Questions On Medicare Formulary Guidelines

Executive Summary

The U.S. Pharmacopeia has been providing congressional committees with information as it moves toward finalizing its model formulary guidelines for the Medicare prescription drug benefit

You may also be interested in...



USP hires former PBM exec as general counsel

Susan de Mars joins U.S. Pharmacopeia as senior VP and general counsel from the law firm Reed Smith Nov. 15. She was formerly senior VP-governmental affairs for benefit manager AdvancePCS, where she focused on Medicare drug benefit issues and the development of compliance guidance for the pharmaceutical industry. USP is in the midst of developing model formulary guidelines for the Medicare prescription drug program (1"The Pink Sheet" Oct. 25, 2004, p. 26). De Mars succeeds Joseph Valentino, who is retiring from USP Dec. 15...

USP hires former PBM exec as general counsel

Susan de Mars joins U.S. Pharmacopeia as senior VP and general counsel from the law firm Reed Smith Nov. 15. She was formerly senior VP-governmental affairs for benefit manager AdvancePCS, where she focused on Medicare drug benefit issues and the development of compliance guidance for the pharmaceutical industry. USP is in the midst of developing model formulary guidelines for the Medicare prescription drug program (1"The Pink Sheet" Oct. 25, 2004, p. 26). De Mars succeeds Joseph Valentino, who is retiring from USP Dec. 15...

Broad Medicare Formularies Would Negatively Impact Rx Industry – PCMA

Strict formulary requirements imposed on plan sponsors under the Medicare prescription drug benefit would be self-defeating for pharmaceutical manufacturers, Pharmaceutical Care Management Association CEO Mark Merritt argued Oct. 25

Related Content

UsernamePublicRestriction

Register

OM010563

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel